Skip to main content
⌘K
·
Launch Terminal
Launch Terminal
Home
SEC Filings
Home
SEC Filings
Filings
Filing Date
Form Type
Company
Description
AI
Link
Learn
MCP
API
Cookie Preferences
Material events
Financial results
Capital raises
Insider transactions
Fund filings
Advanced filters
Any time
Sort
Filings
Filing Date
Form Type
Company
Description
AI
Link
Browse AI-analysed SEC filings
Page 35 of 73 · 7,256 total
LGL: 8-K · leadership change
LGL · 8-K · 2026-10-05
ZGM: 6-K · reverse split
ZGM · 6-K · 2026-10-05
PMVP: 8-K · leadership change
PMVP · 8-K · 2026-10-05
NTR: 6-K · other
NTR · 6-K · 2026-10-05
BBBY: 424B5 · prospectus supplement
BBBY · 424B5 · 2026-10-05
OBA: 8-K · leadership change
OBA · 8-K · 2026-10-05
JAGX: 8-K · dividend
JAGX · 8-K · 2026-10-05
SWKS: 8-K · acquisition merger
SWKS · 8-K · 2026-10-05
QRVO: 8-K · acquisition merger
QRVO · 8-K · 2026-10-05
YPF: 6-K · debt financing
YPF · 6-K · 2026-10-05
GWH: 8-K · delisting
GWH · 8-K · 2026-10-05
INTT: 8-K · earnings release
INTT · 8-K · 2026-10-05
AGPU: 8-K · acquisition merger
AGPU · 8-K · 2026-10-05
CCEP: 6-K · share repurchase
CCEP · 6-K · 2026-10-05
STM: 6-K · share repurchase
STM · 6-K · 2026-10-05
GREE: 8-K · debt financing
GREE · 8-K · 2026-10-05
LPA: 6-K · asset sale
LPA · 6-K · 2026-10-05
SIMA: 8-K · acquisition merger
SIMA · 8-K · 2026-10-05
IMNM: 8-K · material agreement
IMNM · 8-K · 2026-10-05
VATE: 8-K · asset sale
VATE · 8-K · 2026-10-05
PSX: 8-K · leadership change
PSX · 8-K · 2026-10-05
CHRW: 8-K · acquisition merger
CHRW · 8-K · 2026-10-05
LDOS: 8-K · acquisition merger
LDOS · 8-K · 2026-10-05
RRGB: 8-K · debt financing
RRGB · 8-K · 2026-10-05
DFDV: 8-K · earnings release
DFDV · 8-K · 2026-10-05
RXO: 8-K · acquisition merger
RXO · 8-K · 2026-10-05
CHT: 6-K · other
CHT · 6-K · 2026-10-05
FLEX: 8-K · material agreement
FLEX · 8-K · 2026-10-05
SDEV: 8-K · earnings release
SDEV · 8-K · 2026-10-05
EDRY: 6-K · periodic report
EDRY · 6-K · 2026-10-05
FTCI: 8-K · debt financing
FTCI · 8-K · 2026-10-05
FRMM: 8-K · material agreement
FRMM · 8-K · 2026-10-05
BFLY: 8-K · leadership change
BFLY · 8-K · 2026-10-05
TGE: 6-K · foreign private issuer
TGE · 6-K · 2026-10-05
ODV: 6-K · other
ODV · 6-K · 2026-10-05
MNSO: 6-K · share repurchase
MNSO · 6-K · 2026-10-05
AGMH: 6-K · leadership change
AGMH · 6-K · 2026-10-05
RADX: 6-K · clinical trial
RADX · 6-K · 2026-10-05
ALVO: 6-K · fda approval
ALVO · 6-K · 2026-10-05
KARO: 6-K · earnings release
KARO · 6-K · 2026-10-05
MTDR: 8-K · acquisition merger
MTDR · 8-K · 2026-10-05
AZN: 6-K · acquisition merger
AZN · 6-K · 2026-10-05
HROW: 8-K · acquisition merger
HROW · 8-K · 2026-10-05
PTC: 8-K · acquisition merger
PTC · 8-K · 2026-10-05
TRIB: 6-K · proxy statement
TRIB · 6-K · 2026-10-05
SSYS: 6-K · proxy statement
SSYS · 6-K · 2026-10-05
BBBY: 8-K · acquisition merger
BBBY · 8-K · 2026-10-05
FER: 6-K · other
FER · 6-K · 2026-10-05
ELBM: 6-K · leadership change
ELBM · 6-K · 2026-10-05
ECX: 6-K · acquisition merger
ECX · 6-K · 2026-10-05
INSM: 8-K · leadership change
INSM · 8-K · 2026-10-05
WMS: 8-K · acquisition merger
WMS · 8-K · 2026-10-05
TDW: 8-K · material agreement
TDW · 8-K · 2026-10-05
GILT: 6-K · material agreement
GILT · 6-K · 2026-10-05
ALEC: 8-K · material agreement
ALEC · 8-K · 2026-10-05
PBM: 6-K · material agreement
PBM · 6-K · 2026-10-05
MSCLF: 6-K · other
MSCLF · 6-K · 2026-10-05
GEO: 8-K · asset sale
GEO · 8-K · 2026-10-05
NGG: 6-K · earnings release
NGG · 6-K · 2026-10-05
PUK: 6-K · share repurchase
PUK · 6-K · 2026-10-05
ETI-P: 8-K · leadership change
ETI-P · 8-K · 2026-10-05
MGN: 6-K · delisting
MGN · 6-K · 2026-10-05
AVY: 8-K · leadership change
AVY · 8-K · 2026-10-05
DCGO: 8-K · debt financing
DCGO · 8-K · 2026-10-05
LSH: 8-K · material agreement
LSH · 8-K · 2026-10-05
ETN: 8-K · leadership change
ETN · 8-K · 2026-10-05
ICCM: 6-K · regulatory action
ICCM · 6-K · 2026-10-05
NIVF: 6-K · other
NIVF · 6-K · 2026-10-05
ZTO: 6-K · share repurchase
ZTO · 6-K · 2026-10-05
RDY: 6-K · regulatory action
RDY · 6-K · 2026-10-05
JEF: 424B5 · prospectus supplement
JEF · 424B5 · 2026-10-05
JEF: 424B5 · prospectus supplement
JEF · 424B5 · 2026-10-05
JEF: 424B5 · prospectus supplement
JEF · 424B5 · 2026-10-05
JEF: 424B5 · prospectus supplement
JEF · 424B5 · 2026-10-05
PFSA: 8-K · material agreement
PFSA · 8-K · 2026-10-05
ZH: 6-K · share repurchase
ZH · 6-K · 2026-10-05
SGLA: 8-K · acquisition merger
SGLA · 8-K · 2026-10-05
BEKE: 6-K · share repurchase
BEKE · 6-K · 2026-10-05
HDB: 6-K · periodic report
HDB · 6-K · 2026-10-05
SU: 6-K · asset sale
SU · 6-K · 2026-10-05
IX: 6-K · share repurchase
IX · 6-K · 2026-10-05
ALM: 6-K · litigation
ALM · 6-K · 2026-10-05
APXC: 6-K · clinical trial
APXC · 6-K · 2026-10-05
EVTL: 6-K · leadership change
EVTL · 6-K · 2026-10-05
NIU: 6-K · earnings release
NIU · 6-K · 2026-10-05
ATHE: 6-K · clinical trial
ATHE · 6-K · 2026-10-05
NCI: 6-K · amendment
NCI · 6-K · 2026-10-05
TM: 6-K · share repurchase
TM · 6-K · 2026-10-05
PULM: S-3/A · shelf registration
PULM · S-3/A · 2026-10-03
ITUB: 6-K · periodic report
ITUB · 6-K · 2026-10-02
VST: 8-K · debt financing
VST · 8-K · 2026-10-03
MOBX: 424B3 · prospectus supplement
MOBX · 424B3 · 2026-10-02
MOBX: 424B3 · prospectus supplement
MOBX · 424B3 · 2026-10-02
SVM: 6-K · proxy statement
SVM · 6-K · 2026-10-02
PCLA: 6-K · other
PCLA · 6-K · 2026-10-02
SVM: 6-K · proxy statement
SVM · 6-K · 2026-10-02
TNON: S-3 · shelf registration
TNON · S-3 · 2026-10-02
AIBT: 8-K · acquisition merger
AIBT · 8-K · 2026-10-02
NVO: 6-K · fda rejection
NVO · 6-K · 2026-10-02
WKSP: S-3 · shelf registration
WKSP · S-3 · 2026-10-02
‹ Prev
1
4
8
12
16
20
24
28
32
33
34
35
36
37
38
40
44
48
52
56
60
64
68
72
73
Next ›
